From June 1st to June 5th, 2018, the 54thAmerican Society of Clinical Oncology(ASCO) was successfully held in Chicago, United States. ASCO is the largest, most academic and authoritative clinical oncology conference in the world, the theme of the conference is “Delivering Discoveries: Expanding the Reach of Precision Medicine”. Under the leadership of Professor Lang Jinyi, Dean of our hospital and Professor of Oncology, Prof. Li Tao,Deputy Director of Radiotherapy Center and Director of Department of Radiotherapy, Prof. Wang Jie, Director of the Department of Abdominal Radiotherapy, Zhang Peng, Director of Head and Neck Radiotherapy II Ward, and Lai Xin, Physician of Head and Neck Radiotherapy II Ward attended the global academic conference on oncology. More than 39,000 oncologists attended the ASCO Annual Conference. There were also many studies at the ASCO conference in China that were selected as oral presentations and poster presentations. One of the prospective randomized clinical trials led by Director Zhang Peng and completed by our head-and-neck radiotherapy team was reported by ASCO. By randomizing the patients with radical radiotherapy and chemotherapy for head and neck cancer, the team studied the difference between the incidence of adverse reactions in radiotherapy and chemotherapy , changes in nutrition indicators, and psychological state changes in patients with early nutritional support plus regular diet and conventional diets. Studies have shown that early nutritional support can improve the nutrition status of patients with head and neck cancer during radiochemotherapy, reduce the incidence of normal tissue complications and the incidence of adverse psychological mood, and help improve the treatment effect. This clinical trial is still ongoing.
